• NT-219 Re-sensitizes Cancer to Keytruda, Stopping Tumor Progression, Study Shows
  • Opdivo Extends Survival, Has Less Impact on Lives in Head and Neck Cancer Patients Than Standard Chemo, Study Shows
  • Celgene Working with BeiGene to Develop Its PD-1 Inhibitor, BGB-A317, to Treat Solid Tumors
  • Phase 3 Trial to Assess Cabometyx Combo Therapies vs. Sutent in Advanced Kidney Cancer Patients
  • PDS, Merck to Launch Trial Testing Combo Therapy in Treating Certain Head and Neck Cancer Patients
  • $3.75 Million in Grants to Help ViraCyte Continue Working on Therapies to Combat Post-transplant Viruses
  • Gene Expression Analysis Helps Determine Sensitivity to Immunotherapies
  • Mirati Hosts Key Opinion Leader Breakfast on Immuno-oncology Combinations in NYC
  • Cancer Research Institute Announces $1 Million Technology Impact Award Winner
  • Opdivo Keeps Melanoma from Recurring Longer Than Yervoy, Phase 3 Clinical Trial Shows
  • CRI’s 2017 Immunotherapy Patient Series Launches July 8 in San Francisco
  • EFFECTOR to Work with Pfizer and Merck on Evaluating Colorectal Cancer Immunotherapy Combo